Janus-kinase inhibitors in rheumatology

Tarasenko T.M.1, Rekalov D.G.2, Tarasenko O.N.1, Docenko S.Ya.3, Shevchenko M.V.3, Svystun S.I.3

Summary. Janus kinase inhibitors (JAKi) belong to one of the newest classes of targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) and have demonstrated high efficacy in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and other immune-mediated inflammatory diseases. JAKi’s mechanism of action is intracellular disruption of the JAK/STAT pathway, which is critical in the immune response. The convenience of oral JAKi, as opposed to biologics that require parenteral injections, is innovative from a patient perspective. This review discusses the efficacy and safety of JAKi in rheumatic diseases.

No Comments » Add your
Leave a comment